Effect of Acoramidis on Heart Failure–Related Health Status

What is the effect of acoramidis on heart failure–related health status as measured by the Kansas City Cardiomyopathy Questionnaire in patients with transthyretin amyloid cardiomyopathy (ATTR-CM)? In this secondary analysis of the ATTRibute-CM randomized clinical trial among 611 participants (acoramidis: 409; placebo: 202), acoramidis attenuated the decline in heart failure–related health status vs placebo at month 30. Acoramidis was associated with both significantly greater likelihood of survival without worsening health status and improved or maintained health status vs placebo. Beyond the established benefits of acoramidis in improving survival and reducing hospitalizations in ATTR-CM, treatment resulted in better heart failure–related health status relative to placebo.

Corresponding Author: Brett W. Sperry, MD, Saint Luke’s Mid America Heart Institute, 4330 Wornall Rd, Ste 2000, Kansas City, MO 64111 (bsperry@saintlukeskc.org).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.